Home
Drugs
Paclitaxel
Clinical Trials

Clinical Trials Related to Paclitaxel

Related studies linked through entity extraction aliases.

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Status: NOT_YET_RECRUITING
Phase: PHASE2

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Status: COMPLETED
Phase: PHASE1

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

Status: COMPLETED
Phase: PHASE2

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Status: RECRUITING
Phase: PHASE3

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Status: WITHDRAWN
Phase: PHASE2

NUVOLA TRIAL Open-label Multicentre Study

Status: UNKNOWN
Phase: PHASE2

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

Status: COMPLETED
Phase: PHASE1

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Status: RECRUITING
Phase: PHASE2

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

Status: WITHDRAWN
Phase: PHASE1

Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

Status: TERMINATED
Phase: PHASE2

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Status: COMPLETED
Phase: PHASE2

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Status: COMPLETED
Phase: PHASE2

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: TERMINATED
Phase: PHASE3

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2